Current Cancer Drug Targets
Volume 21, 11 Issues, 2021
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Contents
Current Cancer Drug Targets, Volume 17 - Number 2
Biography Open Access
Review Article
Anticancer Potential and Molecular Targets of Pristimerin: A Mini- Review
, 17(2): 100 - 108Bashir A. Yousef, Hozeifa M. Hassan, Lu-Yong Zhang and Zhen-Zhou Jiang
DOI: 10.2174/1568009616666160112105824
Anticancer Potential and Molecular Targets of Pristimerin: A Mini- Review
Review Article
Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors
, 17(2): 109 - 121Alessandro Federico, Silvia Zappavigna, Marcello Dallio, Gabriella Misso, Francesco Merlino, Carmela Loguercio, Ettore Novellino, Paolo Grieco and Michele Caraglia
DOI: 10.2174/1568009616666160621101248
Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors
Review Article
Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
, 17(2): 122 - 136Nan Wang, Yue Wu, Jinlei Bian, Xue Qian, Hongzhi Lin, Haopeng Sun, Qidong You and Xiaojin Zhang
DOI: 10.2174/1568009616666160216125833
Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Review Article
Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma
, 17(2): 137 - 157Hazem I. Assi and Rita E. Assi
DOI: 10.2174/1568009616666160719120053
Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma
Review Article
Targeting Key Metabolic Enzymes Involved in Lipid and Protein Biosyntheses for Breast Anticancer Therapies
, 17(2): 158 - 168Mounia Guerram, Aida Mejda Hamdi, Lu-Yong Zhang and Zhenzhou Jiang
DOI: 10.2174/1568009616666160603123014
Targeting Key Metabolic Enzymes Involved in Lipid and Protein Biosyntheses for Breast Anticancer Therapies
Research Article
Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region
, 17(2): 169 - 176Yuanxin Liang, Jinwu Zeng, Linda Jelicks, Shengwei Ma, Jing Liu, Jingsong Mei, Roman Perez-Soler and Yiyu Zou
DOI: 10.2174/1568009616666160331124759
Research Article
Grid-independent Descriptors (GRIND) Analysis and SAR Guided Molecular Docking Studies to Probe Selectivity Profiles of Inhibitors of Multidrug Resistance Transporters ABCB1 and ABCG2
, 17(2): 177 - 190Talha Shafi and Ishrat Jabeen
DOI: 10.2174/1568009616666160901094140
Grid-independent Descriptors (GRIND) Analysis and SAR Guided Molecular Docking Studies to Probe Selectivity Profiles of Inhibitors of Multidrug Resistance Transporters ABCB1 and ABCG2
Research Article
CYR61 Confers the Sensitivity to Aromatase Inhibitor Letrozole in ER Positive Breast Carcinoma
, 17(2): 191 - 197Xiaoqing Jia, Guangyu Liu, Jingyi Cheng, Zhenzhou Shen and Zhimin Shao
DOI: 10.2174/1568009616666160426125058
CYR61 Confers the Sensitivity to Aromatase Inhibitor Letrozole in ER Positive Breast Carcinoma
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
COPE Compliant
About the Journal
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Cancer Drug Targets was launched in 2001. Dr. Ruiwen Zhang serves as the Editor-in-Chief of the journal.
Advertisement
Webmaster Contact: info@benthamscience.net